PTHS — Pelthos Therapeutics Inc.

PTHS closed at $16.54 (+5.08%) on Oct 29, 2026. Active shelf registration (S-3, Feb 2026). Float: 133.7K shares. Latest SEC filing: 8-K on Oct 30, 2026.

Opening the full analysis uses 1 of your 3 free tickers today.

Open full analysis

Chart, dilution, float and news for PTHS in the TickerWise workspace.

Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older. It also provides NITRICIL, a proprietary nitric oxide-based technology platform. The company was formerly known as Channel Therapeutics Corporation and changed its name to Pelthos Therapeutics Inc. in July 2025. Pelthos Therapeutics Inc. was founded in 2002 and is based in Durham, North Carolina.

Company profile

• Sector: Healthcare
• Industry: Biotechnology
• Country: US
• Exchange: AMEX
• Employees: 4
• Website: https://pelthos.com

Latest SEC filings for PTHS

• 2026-10-308-K
• 2026-10-30425
• 2026-08-18ARS
• 2026-05-288-K
• 2026-05-218-K
• 2026-05-15SCHEDULE 13G/A
• 2026-05-148-K
• 2026-05-1410-Q
• 2026-05-08SCHEDULE 13G/A
• 2026-04-203

Latest PTHS news

• 2026-10-30Pelthos Therapeutics stock sinks after Castle Creek merger deal Read article
• 2026-10-06Pelthos Therapeutics Announces Expanded Formulary Coverage for ZELSUVMI® (berdazimer) Topical Gel, 10.3% Read article

Related companies

• VRTX — Vertex Pharmaceuticals Incorporated
• MRNA — Moderna, Inc.
• REGN — Regeneron Pharmaceuticals, Inc.
• ARGX — argenx SE
• ALNY — Alnylam Pharmaceuticals, Inc.
• INSM — Insmed Incorporated
• RVMD — Revolution Medicines, Inc.
• UTHR — United Therapeutics Corporation

Opening the full analysis uses 1 of your 3 free tickers today.

Open full analysis

Educational tool only — not investment advice.